An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients.

by Elizabeth Colston, Dennis Grasela, David Gardiner, R Pat Bucy, Blisse Vakkalagadda, Alan J Korman, Israel Lowy
Published 2018-01-01

Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy

by C. Lance Cowey, Nicholas J. Robert, Janet L. Espirito, Kalatu Davies, Jennifer Frytak, Israel Lowy, Matthew G. Fury
Published 2020-10-01

264 Correlation of virus-specific CD8+ T cells to clinical response following treatment with Pexa-Vec and Cemiplimab in patients with advanced renal cell carcinoma

by Gavin Thurston, Israel Lowy, Vladimir Jankovic, Myles Dillon, Lianjie Li, Jeongsook Bang, Nicholas Gaspar, Jessica Kuhnert, Nathalie Fiaschi, Glenn Kroog, Kyoung Soo Ha, Raquel Deering
Published 2020-11-01

Tumor-reprogrammed resident T cells resist radiation to control tumors

by Ainhoa Arina, Michael Beckett, Christian Fernandez, Wenxin Zheng, Sean Pitroda, Steven J. Chmura, Jason J. Luke, Martin Forde, Yuzhu Hou, Byron Burnette, Helena Mauceri, Israel Lowy, Tasha Sims, Nikolai Khodarev, Yang-Xin Fu, Ralph R. Weichselbaum
Published 2019-09-01

A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma

by Robert G. Maki, Achim A. Jungbluth, Sacha Gnjatic, Gary K. Schwartz, David R. D’Adamo, Mary Louise Keohan, Michael J. Wagner, Kelly Scheu, Rita Chiu, Erika Ritter, Jennifer Kachel, Israel Lowy, Lloyd J. Old, Gerd Ritter
Published 2013-01-01

A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus...

by David Gardiner, Jay Lalezari, Eric Lawitz, Michael DiMicco, Rheem Ghalib, K Rajender Reddy, Kyong-Mi Chang, Mark Sulkowski, Steven O' Marro, Jeffrey Anderson, Bing He, Vikram Kansra, Fiona McPhee, Megan Wind-Rotolo, Dennis Grasela, Mark Selby, Alan J Korman, Israel Lowy
Published 2013-01-01

428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

by Marcus Butler, Rogerio Neves, Lisa Licitra, Israel Lowy, Zeynep Eroglu, Karl Lewis, Leonel Hernandez-Aya, Axel Hauschild, Emmanuel Okoye, Siyu Li, Jean-Francois Baurain, Oliver Bechter, Ketty Peris, Aleksandar Sekulic, Alexander Stratigos, Lara Dunn, Anne Lynn Chang, Michael Migden, Kosalai Mohan, Ebony Coates, Emily Ruiz, Frank Seebach, David Weinreich, George Yancopoulos, Timothy Bowler, Matthew Fury
Published 2020-11-01